Statin therapy has proven benefits in reducing LDL cholesterol and preventing cardiovascular events in individuals with diabetes and ASCVD
Working solution concentration: 0.22 mg/mL This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details
GLP-1 is an endogenous incretin peptide secreted from intestinal L-cells after food intake, exerting glucose-dependent hypoglycemic regulation without triggering hypoglycemia risk under normal low-sugar status
Lightheadedness: Some patients experience brief dizziness shortly after injection, particularly during the first few doses
The table above reflects general market positioning and should be verified against current provider pricing, as the compounded GLP-1 market shifts frequently
Today, Novo Nordisk estimates that just under 20 million people are treated with GLP-1 drugs.4 Given a well-stocked pipeline, a substantial global addressable population (the obese population alone is projected to exceed 1.2 billion by 20305), and in light of the very beneficial clinical profile of these drugs, it is plausible that over 100 million patients worldwide will be treated with GLP-1s in the near future